Good sleuthing on ENTA, although I would temper the enthusiasm for ABT-493 to some degree by nitpicking that “pan-genotypic activity” in preclinical studies is not exactly the same as asserting that the ABT-493 + ABT-530 regimen will be pan-genotypic (which the companies have not yet done).
Market Data 
Markets 
AI
